ES2148526T3 - Formulaciones liquidas de ifn-beta. - Google Patents

Formulaciones liquidas de ifn-beta.

Info

Publication number
ES2148526T3
ES2148526T3 ES95921749T ES95921749T ES2148526T3 ES 2148526 T3 ES2148526 T3 ES 2148526T3 ES 95921749 T ES95921749 T ES 95921749T ES 95921749 T ES95921749 T ES 95921749T ES 2148526 T3 ES2148526 T3 ES 2148526T3
Authority
ES
Spain
Prior art keywords
beta
formulations
ifn
liquid formulations
polyol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95921749T
Other languages
English (en)
Inventor
Fabrizio Samaritani
Patrizia Natale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2148526T3 publication Critical patent/ES2148526T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Abstract

FORMULACIONES LIQUIDAS DE INTERFERON-BETA ESTABILIZADAS CON UN POLIOL, UN AZUCAR NO REDUCTOR O UN AMINOACIDO. EN PARTICULAR, LAS FORMULACIONES SE ESTABILIZAN CON UN POLIOL, COMO PUEDE SER EL MANITOL. LAS FORMULACIONES, PREFERIBLEMENTE, INCLUYEN ADEMAS UN AMORTIGUADOR, COMO PUEDE SER UN AMORTIGUADOR DE ACETATO, CON UN PH COMPRENDIDO ENTRE 3.0 Y 4.0 Y ALBUMINA HUMANA EN UNA CANTIDAD MINIMA. EL INTERFERON BETA ES PREFERIBLEMENTE RECOMBINANTE.
ES95921749T 1994-05-16 1995-05-15 Formulaciones liquidas de ifn-beta. Expired - Lifetime ES2148526T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM940300A IT1272252B (it) 1994-05-16 1994-05-16 Formulazioni liquide di interferone beta

Publications (1)

Publication Number Publication Date
ES2148526T3 true ES2148526T3 (es) 2000-10-16

Family

ID=11402534

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95921749T Expired - Lifetime ES2148526T3 (es) 1994-05-16 1995-05-15 Formulaciones liquidas de ifn-beta.

Country Status (13)

Country Link
US (2) US6852314B1 (es)
EP (1) EP0759775B1 (es)
JP (1) JP3701675B2 (es)
AT (1) ATE194917T1 (es)
AU (1) AU704827B2 (es)
CA (1) CA2190465A1 (es)
DE (1) DE69518152T2 (es)
DK (1) DK0759775T3 (es)
ES (1) ES2148526T3 (es)
GR (1) GR3034309T3 (es)
IT (1) IT1272252B (es)
PT (1) PT759775E (es)
WO (1) WO1995031213A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
DE69729880T3 (de) * 1996-12-24 2012-05-10 Biogen Idec Ma Inc. Stabile flüssige interferon-zubereitungen
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
PT1224940E (pt) * 1997-09-23 2005-01-31 Rentschler Biotech Gmbh Formulacoes liquidas de intrferao beta
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
AU3473999A (en) * 1998-04-03 1999-10-25 Chiron Corporation Injectable igf-formulations containing succinate as buffering agent
WO2002038170A2 (en) * 2000-11-07 2002-05-16 Chiron Corporation Stabilized inteferon compositions
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
UY27373A1 (es) * 2001-07-09 2003-02-28 Schering Ag Formulaciones de interferón beta-humano
TWI272948B (en) * 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US7879320B2 (en) * 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
EA010979B1 (ru) 2004-06-01 2008-12-30 Арес Трейдинг С.А. Стабилизированные жидкие препаративные формы интерферона
US7913435B1 (en) * 2005-09-28 2011-03-29 Hummel Iii John F Vehicle display bracket system
WO2009080699A2 (en) * 2007-12-20 2009-07-02 Merck Serono S.A. Peg-interferon-beta formulations
US20120269770A1 (en) * 2010-11-22 2012-10-25 Mark Brader Stable Preserved Compositions of Interferon-Beta
WO2017170626A1 (ja) * 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5821691A (ja) * 1981-07-29 1983-02-08 Mochida Pharmaceut Co Ltd α−及びβ−インタ−フェロンの精製方法
EP0080879B1 (en) * 1981-11-28 1986-10-01 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
AU1234383A (en) 1982-03-17 1983-09-22 Inter-Yeda Ltd. Interferon stabilised with polyvinyl-pyrrolidone
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL88233A (en) 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon

Also Published As

Publication number Publication date
WO1995031213A1 (en) 1995-11-23
CA2190465A1 (en) 1995-11-23
AU704827B2 (en) 1999-05-06
DE69518152T2 (de) 2000-12-14
ITRM940300A0 (it) 1994-05-16
JP3701675B2 (ja) 2005-10-05
IT1272252B (it) 1997-06-16
DK0759775T3 (da) 2000-11-13
JPH10500125A (ja) 1998-01-06
GR3034309T3 (en) 2000-12-29
US6852314B1 (en) 2005-02-08
AU2670495A (en) 1995-12-05
ATE194917T1 (de) 2000-08-15
EP0759775B1 (en) 2000-07-26
DE69518152D1 (de) 2000-08-31
US7407651B2 (en) 2008-08-05
US20040265270A1 (en) 2004-12-30
ITRM940300A1 (it) 1995-11-16
EP0759775A1 (en) 1997-03-05
PT759775E (pt) 2000-11-30

Similar Documents

Publication Publication Date Title
ES2148526T3 (es) Formulaciones liquidas de ifn-beta.
AU558966B2 (en) Interferon and amino acid as stabilizer
FI905003A0 (fi) Glykosaminoglykan modifierat protein.
JPS56139422A (en) Sterilized and therapeutically active protein composition
IT8520242A0 (it) Polipeptide umano fisiologicamente attivo.
IT8323559A0 (it) Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
IT1232827B (it) Proteine biologicamente attive, formulazioni che le contengono e metodo per prepararle ed applicarle
DE3882593T2 (de) Polypeptid und dessen Herstellung.
GB2183658B (en) Human manganese superoxide dismutase analog, plasmid for its expression and method of recovering it in enzymatically active form.
ATE109206T1 (de) O-glycosylierter igf-1.
DE69106407T2 (de) Verfahren zur Herstellung von rekombinantem menschlichem gamma-Interferon ohne Cystein und ohne Methionin am N-Terminal.
EP0212912A3 (en) Calcitonin analogs with c-therminal d-amino acid substituents
EP0315118A3 (en) Dna coding for endothelin and use thereof
IL89989A0 (en) Expression of human interleukin-2 in methylotrophic yeasts
IT8420419V0 (it) Struttura di testa, provvista di occhi mobili, applicabili su pupazzi in genere.
JPS57192610A (en) Strut and crosspiece in prefabricated frame body
AU92306S (en) Buddha figurine
TH2087EX (th) โครงสำหรับชั้นวางของ
IT7859341V0 (it) Tavoletta di supporto di bottiglie e bicchieri da applicare all'asta di sostegno di ombrelloni da sole.
IT1230830B (it) Perfezionamento nei telai di scocca e nelle ruote di motocicli
ES8500062A1 (es) Un metodo de estabilizar interferon b.
NO820958L (no) Fremgangsmaate for enzymatisk erstatning av b-30-aminosyren i insulin.
ATE92106T1 (de) Polypeptid und dessen herstellung.
ZA868610B (en) Human manganese superoxide dismutase cdna,its expression in bacteria and method of recovering enzymatically active human manganese superoxide dismutase
JO1209B1 (en) Pharmacy formulations that include human insulin and the human insulin component.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759775

Country of ref document: ES